Xactly Corp

xactlycorp.com

Xactly delivers a scalable, enterprise platform for planning and incenting sales organizations, including sales quota and territory planning, incentive compensation management, and predictive analytics. Using this powerful sales performance management (SPM) portfolio, customers mitigate risk, accelerate sales performance, and increase business agility. Combined with Xactly Insights™-- the industry’s only empirical big data platform, Xactly empowers companies with real-time compensation insights and benchmarking data that maximize the bottom line. With an open, standards-based architecture, Xactly seamlessly integrates within an enterprise’s existing infrastructure, with the ability to work with any ERP, CRM, or HCM application, while meeting the highest enterprise standards in security, reliability, and privacy.

C-Suite On Deck

Responsive image

Q&A with Erik Charles, Vice President and Solutions Evangelist at Xactly Corporation

MEDIA 7 | October 7, 2019

Erik Charles, Vice President and Solutions Evangelist at Xactly Corporation is an accomplished professional with over two decades of experience in Marketing, Consulting, and Product Evangelization. Erik focuses on helping companies drive expansion and growth by better aligning positions, responsibilities, and incentives. Erik serves as a subject matter expert in the area of Sales Performance Management to ensure that Xactly’s marketing, sales and product teams have the necessary strategic input for industry leading messaging, positioning, and future direction. MEDIA 7: When did you start working and what was it? ERIK CHARLES:  In early 1980s, I wrote software on TRS-80 model II coded in BASIC to enable for computerized quotes for a life insurance agency. I was in middle school at the time, that was a contract work. My next job was at a software store back when software used to be bundled up into a cardboard box with inserted floppy disks and then it went on from there. M7: You have an astounding experience of over two decades with industry pioneers like Apple, Sun Microsystems, Canon and recently Xactly Corporation. What has been the driving force behind your remarkable career? EC: There are two things: as a marketer, I don’t believe in mistakes, I only believe in experiments and what we can learn from them, that has kept me moving forward. I keep on trying new things and seeing what works. I assume that just because it worked last week doesn’t mean it’s going to work tomorrow. So, I’ve never allowed myself to get into a rut. I have always been more than willing to find people who can provide excellent advice at critical moments, even on a specific direction. Finding someone that I can speak with, that can give me a few tips, tricks, hints, ideas, direction or path on moving on. So, I have never been afraid to ask just how could I do this better. Read More

Events

Related News

MedTech, Industrial Impact

TWIST BIOSCIENCE ENTERS INTO THIRD COLLABORATION WITH ASTELLAS TO SUPPORT ANTIBODY DISCOVERY FOR IMMUNOTHERAPIES

Businesswire | April 21, 2023

news image

Twist Bioscience Corporation a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a collaboration with Astellas Pharma Inc. by which Astellas will license a suite of Twist’s VHH antibody libraries to be used by Astellas for drug discovery and development. “We are pleased to extend our collaboration with Astellas to three agreements across two groups within the company, showcasing our ab...

Read More

Industrial Impact

LUMMUS AND SYNTHOS ADVANCE BIO-BUTADIENE TECHNOLOGY DEVELOPMENT TO PRODUCE SUSTAINABLE RUBBER

Lummus Technology, LLC | February 14, 2022

news image

Lummus Technology announced that its Green Circle business and Synthos S.A. have reached a major milestone in the development of advanced bio-butadiene technology. After completing a successful feasibility study in 2021, Lummus and Synthos have concluded that the bio-butadiene technology is ready for implementation, and the companies have agreed to move into the engineering and design phase of the project. Given the confidence in the technology and the strong market demand for ren...

Read More

Cell and Gene Therapy

BIOINVENT AND TRANSGENE RECEIVE CTA APPROVAL FOR PHASE L/LLA STUDY OF NOVEL ONCOLYTIC VACCINIA VIRUS BT-001

BioInvent | December 22, 2020

news image

BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech organization focused in on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, and Transgene (Euronext Paris: TNG), a biotech organization that designs and develops infection based for the therapy of cancer, reported they have received administrative endorsement in Belgium for a clinical trial application (CTA) for a Phase l/lla study of the novel oncolytic vacc...

Read More

Cell and Gene Therapy

EXUMA BIOTECH COMPLETES SERIES B2 TO ADVANCE NOVEL CELL & GENE THERAPIES

EXUMA Biotech Corp. | December 22, 2021

news image

EXUMA Biotech, Corp., a clinical-stage biotechnology company discovering and developing cell and gene therapies and delivery solutions for liquid and solid tumors, announced the completion of a $41 million Series B2 financing. The Series B2 brings the total capital raised since its inception to approximately $130 million. Proceeds will be used to support further development of EXUMA's autologous subcutaneous rPOC CAR-TaNK platform for hematologic and solid tumors and con...

Read More
news image

MedTech, Industrial Impact

TWIST BIOSCIENCE ENTERS INTO THIRD COLLABORATION WITH ASTELLAS TO SUPPORT ANTIBODY DISCOVERY FOR IMMUNOTHERAPIES

Businesswire | April 21, 2023

Twist Bioscience Corporation a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a collaboration with Astellas Pharma Inc. by which Astellas will license a suite of Twist’s VHH antibody libraries to be used by Astellas for drug discovery and development. “We are pleased to extend our collaboration with Astellas to three agreements across two groups within the company, showcasing our ab...

Read More
news image

Industrial Impact

LUMMUS AND SYNTHOS ADVANCE BIO-BUTADIENE TECHNOLOGY DEVELOPMENT TO PRODUCE SUSTAINABLE RUBBER

Lummus Technology, LLC | February 14, 2022

Lummus Technology announced that its Green Circle business and Synthos S.A. have reached a major milestone in the development of advanced bio-butadiene technology. After completing a successful feasibility study in 2021, Lummus and Synthos have concluded that the bio-butadiene technology is ready for implementation, and the companies have agreed to move into the engineering and design phase of the project. Given the confidence in the technology and the strong market demand for ren...

Read More
news image

Cell and Gene Therapy

BIOINVENT AND TRANSGENE RECEIVE CTA APPROVAL FOR PHASE L/LLA STUDY OF NOVEL ONCOLYTIC VACCINIA VIRUS BT-001

BioInvent | December 22, 2020

BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech organization focused in on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, and Transgene (Euronext Paris: TNG), a biotech organization that designs and develops infection based for the therapy of cancer, reported they have received administrative endorsement in Belgium for a clinical trial application (CTA) for a Phase l/lla study of the novel oncolytic vacc...

Read More
news image

Cell and Gene Therapy

EXUMA BIOTECH COMPLETES SERIES B2 TO ADVANCE NOVEL CELL & GENE THERAPIES

EXUMA Biotech Corp. | December 22, 2021

EXUMA Biotech, Corp., a clinical-stage biotechnology company discovering and developing cell and gene therapies and delivery solutions for liquid and solid tumors, announced the completion of a $41 million Series B2 financing. The Series B2 brings the total capital raised since its inception to approximately $130 million. Proceeds will be used to support further development of EXUMA's autologous subcutaneous rPOC CAR-TaNK platform for hematologic and solid tumors and con...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Q&A with Erik Charles, Vice President and Solutions Evangelist at Xactly Corporation

MEDIA 7 | October 7, 2019

Erik Charles, Vice President and Solutions Evangelist at Xactly Corporation is an accomplished professional with over two decades of experience in Marketing, Consulting, and Product Evangelization. Erik focuses on helping companies drive expansion and growth by better aligning positions, responsibilities, and incentives. Erik serves as a subject matter expert in the area of Sales Performance Management to ensure that Xactly’s marketing, sales and product teams have the necessary strategic input for industry leading messaging, positioning, and future direction. MEDIA 7: When did you start working and what was it? ERIK CHARLES:  In early 1980s, I wrote software on TRS-80 model II coded in BASIC to enable for computerized quotes for a life insurance agency. I was in middle school at the time, that was a contract work. My next job was at a software store back when software used to be bundled up into a cardboard box with inserted floppy disks and then it went on from there. M7: You have an astounding experience of over two decades with industry pioneers like Apple, Sun Microsystems, Canon and recently Xactly Corporation. What has been the driving force behind your remarkable career? EC: There are two things: as a marketer, I don’t believe in mistakes, I only believe in experiments and what we can learn from them, that has kept me moving forward. I keep on trying new things and seeing what works. I assume that just because it worked last week doesn’t mean it’s going to work tomorrow. So, I’ve never allowed myself to get into a rut. I have always been more than willing to find people who can provide excellent advice at critical moments, even on a specific direction. Finding someone that I can speak with, that can give me a few tips, tricks, hints, ideas, direction or path on moving on. So, I have never been afraid to ask just how could I do this better. Read More